Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Healing of erosive esophagitis and reduction of related symptoms.
* Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **GERD (Symptomatic Relief):** 20 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily, may be increased to 80 mg orally or intravenously twice daily. Doses >80 mg daily should be divided and given every 12 hours.
## Pediatric Dosing
* **Erosive Esophagitis (Age 5 to 11 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (Age 5 to 11 years):** 40 mg orally once daily for up to 8 weeks, if insufficient response to 20 mg.
* **Erosive Esophagitis (Age 12 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* **GERD (Age 5 to 17 years):** 20 mg orally once daily for up to 4 weeks.
Dosing for younger children or for IV administration in pediatrics is less established and may depend on local protocols and clinician judgment.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (can be severe), vitamin B12 deficiency with long-term use.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, erlotinib, mycophenolate mofetil. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 Substrates:** Fluoxetine, sertraline, citalopram, escitalopram, diazepam, phenytoin. Pantoprazole is a moderate inhibitor of CYP2C19 and may increase levels of these drugs.
* **CYP3A4 Substrates:** Atorvastatin. Pantoprazole may increase atorvastatin levels.
## Monitoring
* Magnesium levels, especially in patients on long-term therapy or concomitant diuretic use.
* Vitamin B12 levels with long-term therapy.
* Bone mineral density screening may be considered in patients at risk for osteoporosis.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* Enteric-coated tablets should not be crushed or chewed.
* IV administration is an alternative for patients unable to take oral medications.
* Long-term use is associated with increased risk of *C. difficile* infection, bone fractures, hypomagnesemia, and vitamin B12 deficiency. PPIs should be used at the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current official prescribing information and relevant literature for complete and up-to-date details before making any clinical decisions.
